193 related articles for article (PubMed ID: 36273892)
1. A Japanese case of melanoma of unknown origin with a rare BRAF
Kuriyama H; Kimura T; Mizuhashi S; Nishimura Y; Kanemaru H; Kajihara I; Makino K; Aoi J; Matsui H; Fukushima S
Drug Discov Ther; 2022 Nov; 16(5):256-257. PubMed ID: 36273892
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
3. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
[TBL] [Abstract][Full Text] [Related]
6. The clinical characteristics of melanoma with BRAF V600R mutation: a case series study.
Malkhasyan KA; Rooney SL; Snow AN; Swick BL; Milhem MM; Zakharia Y
Melanoma Res; 2020 Feb; 30(1):107-112. PubMed ID: 31305324
[TBL] [Abstract][Full Text] [Related]
7. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
8. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
[TBL] [Abstract][Full Text] [Related]
9. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.
Comito F; Aprile M; Pagani R; Siepe G; Sperandi F; Gruppioni E; Altimari A; De Biase D; Melotti B
Melanoma Res; 2022 Dec; 32(6):477-484. PubMed ID: 36039514
[TBL] [Abstract][Full Text] [Related]
11. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G
J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675
[TBL] [Abstract][Full Text] [Related]
12. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
13. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
14. Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M; Dalle S; Mortier L; Dalac S; Leccia MT; Dutriaux C; Montaudié H; de Quatrebarbes J; Lesimple T; Brunet-Possenti F; Saiag P; Maubec E; Legoupil D; Stoebner PE; Arnault JP; Lefevre W; Lebbe C; Dereure O
JCO Precis Oncol; 2022 Nov; 6():e2200075. PubMed ID: 36356284
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
16. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
Heinzerling L; Kühnapfel S; Meckbach D; Baiter M; Kaempgen E; Keikavoussi P; Schuler G; Agaimy A; Bauer J; Hartmann A; Kiesewetter F; Schneider-Stock R
Br J Cancer; 2013 May; 108(10):2164-71. PubMed ID: 23579220
[TBL] [Abstract][Full Text] [Related]
17. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
18. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
[TBL] [Abstract][Full Text] [Related]
19. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
20. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban R
J Transl Med; 2010 Jul; 8():67. PubMed ID: 20630094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]